These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
454 related articles for article (PubMed ID: 30594229)
1. Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase. Mandell BF; Yeo AE; Lipsky PE Arthritis Res Ther; 2018 Dec; 20(1):286. PubMed ID: 30594229 [TBL] [Abstract][Full Text] [Related]
2. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Baraf HS; Becker MA; Gutierrez-Urena SR; Treadwell EL; Vazquez-Mellado J; Rehrig CD; Ottery FD; Sundy JS; Yood RA Arthritis Res Ther; 2013 Sep; 15(5):R137. PubMed ID: 24286509 [TBL] [Abstract][Full Text] [Related]
3. Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout. Johnson RJ; Choi HK; Yeo AE; Lipsky PE Hypertension; 2019 Jul; 74(1):95-101. PubMed ID: 31079535 [TBL] [Abstract][Full Text] [Related]
11. Pegloticase treatment of chronic refractory gout: Update on efficacy and safety. Schlesinger N; Lipsky PE Semin Arthritis Rheum; 2020 Jun; 50(3S):S31-S38. PubMed ID: 32620200 [TBL] [Abstract][Full Text] [Related]
12. Development of a multivariable improvement measure for gout. Schlesinger N; Edwards NL; Yeo AE; Lipsky PE Arthritis Res Ther; 2020 Jun; 22(1):164. PubMed ID: 32600452 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. Sundy JS; Baraf HS; Yood RA; Edwards NL; Gutierrez-Urena SR; Treadwell EL; Vázquez-Mellado J; White WB; Lipsky PE; Horowitz Z; Huang W; Maroli AN; Waltrip RW; Hamburger SA; Becker MA JAMA; 2011 Aug; 306(7):711-20. PubMed ID: 21846852 [TBL] [Abstract][Full Text] [Related]
14. Pegloticase: in treatment-refractory chronic gout. Lyseng-Williamson KA Drugs; 2011 Nov; 71(16):2179-92. PubMed ID: 22035516 [TBL] [Abstract][Full Text] [Related]
15. Interventions for tophi in gout. Sriranganathan MK; Vinik O; Bombardier C; Edwards CJ Cochrane Database Syst Rev; 2014 Oct; (10):CD010069. PubMed ID: 25330136 [TBL] [Abstract][Full Text] [Related]
16. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. Baraf HS; Yood RA; Ottery FD; Sundy JS; Becker MA J Clin Rheumatol; 2014 Dec; 20(8):427-32. PubMed ID: 25417679 [TBL] [Abstract][Full Text] [Related]
17. Pegloticase for chronic gout. Anderson A; Singh JA Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008335. PubMed ID: 20238366 [TBL] [Abstract][Full Text] [Related]
18. Pegloticase failure and a possible solution: Immunosuppression to prevent intolerance and inefficacy in patients with gout. Berhanu AA; Krasnokutsky S; Keenan RT; Pillinger MH Semin Arthritis Rheum; 2017 Jun; 46(6):754-758. PubMed ID: 27769591 [TBL] [Abstract][Full Text] [Related]
19. Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial. Botson JK; Obermeyer K; LaMoreaux B; Zhao L; Weinblatt ME; Peterson J Arthritis Res Ther; 2022 Dec; 24(1):281. PubMed ID: 36575505 [TBL] [Abstract][Full Text] [Related]
20. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Lipsky PE; Calabrese LH; Kavanaugh A; Sundy JS; Wright D; Wolfson M; Becker MA Arthritis Res Ther; 2014 Mar; 16(2):R60. PubMed ID: 24588936 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]